These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

502 related articles for article (PubMed ID: 19636010)

  • 21. Final results of a phase I radioimmunotherapy trial using (186)Re-epratuzumab for the treatment of patients with non-Hodgkin's lymphoma.
    Postema EJ; Raemaekers JM; Oyen WJ; Boerman OC; Mandigers CM; Goldenberg DM; van Dongen GA; Corstens FH
    Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3995S-4002S. PubMed ID: 14506199
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
    Wiernik PH; Lossos IS; Tuscano JM; Justice G; Vose JM; Cole CE; Lam W; McBride K; Wride K; Pietronigro D; Takeshita K; Ervin-Haynes A; Zeldis JB; Habermann TM
    J Clin Oncol; 2008 Oct; 26(30):4952-7. PubMed ID: 18606983
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase I/II study examining pentostatin, chlorambucil, and theophylline in patients with relapsed chronic lymphocytic leukemia and non-Hodgkin's lymphoma.
    Willis CR; Goodrich A; Park K; Waselenko JK; Lucas M; Reese A; Diehl LF; Grever MR; Byrd JC; Flinn IW
    Ann Hematol; 2006 May; 85(5):301-7. PubMed ID: 16518606
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab.
    Lindén O; Hindorf C; Cavallin-Ståhl E; Wegener WA; Goldenberg DM; Horne H; Ohlsson T; Stenberg L; Strand SE; Tennvall J
    Clin Cancer Res; 2005 Jul; 11(14):5215-22. PubMed ID: 16033839
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group.
    Witzig TE; Vukov AM; Habermann TM; Geyer S; Kurtin PJ; Friedenberg WR; White WL; Chalchal HI; Flynn PJ; Fitch TR; Welker DA
    J Clin Oncol; 2005 Feb; 23(6):1103-8. PubMed ID: 15657404
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Distinct apoptotic signaling characteristics of the anti-CD40 monoclonal antibody dacetuzumab and rituximab produce enhanced antitumor activity in non-Hodgkin lymphoma.
    Lewis TS; McCormick RS; Emmerton K; Lau JT; Yu SF; McEarchern JA; Grewal IS; Law CL
    Clin Cancer Res; 2011 Jul; 17(14):4672-81. PubMed ID: 21610152
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I therapy study of 186Re-labeled chimeric monoclonal antibody U36 in patients with squamous cell carcinoma of the head and neck.
    Colnot DR; Quak JJ; Roos JC; van Lingen A; Wilhelm AJ; van Kamp GJ; Huijgens PC; Snow GB; van Dongen GA
    J Nucl Med; 2000 Dec; 41(12):1999-2010. PubMed ID: 11138685
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma.
    Yamamoto K; Utsunomiya A; Tobinai K; Tsukasaki K; Uike N; Uozumi K; Yamaguchi K; Yamada Y; Hanada S; Tamura K; Nakamura S; Inagaki H; Ohshima K; Kiyoi H; Ishida T; Matsushima K; Akinaga S; Ogura M; Tomonaga M; Ueda R
    J Clin Oncol; 2010 Mar; 28(9):1591-8. PubMed ID: 20177026
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II clinical trial of bolus infusion anti-B4 blocked ricin immunoconjugate in patients with relapsed B-cell non-Hodgkin's lymphoma.
    Multani PS; O'Day S; Nadler LM; Grossbard ML
    Clin Cancer Res; 1998 Nov; 4(11):2599-604. PubMed ID: 9829722
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors.
    de Vos S; Forero-Torres A; Ansell SM; Kahl B; Cheson BD; Bartlett NL; Furman RR; Winter JN; Kaplan H; Timmerman J; Whiting NC; Drachman JG; Advani R
    J Hematol Oncol; 2014 Jun; 7():44. PubMed ID: 24919462
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia.
    Furman RR; Forero-Torres A; Shustov A; Drachman JG
    Leuk Lymphoma; 2010 Feb; 51(2):228-35. PubMed ID: 20038235
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma.
    Robinson KS; Williams ME; van der Jagt RH; Cohen P; Herst JA; Tulpule A; Schwartzberg LS; Lemieux B; Cheson BD
    J Clin Oncol; 2008 Sep; 26(27):4473-9. PubMed ID: 18626004
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase-II study of the new aza-anthracenedione, BBR 2778, in patients with relapsed aggressive non-Hodgkin's lymphomas.
    Borchmann P; Morschhauser F; Parry A; Schnell R; Harousseau JL; Gisselbrecht C; Rudolph C; Wilhelm M; Günther H; Pfreundschuh DM; Camboni G; Engert A
    Haematologica; 2003 Aug; 88(8):888-94. PubMed ID: 12935976
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas.
    Aghajanian C; Burris HA; Jones S; Spriggs DR; Cohen MB; Peck R; Sabbatini P; Hensley ML; Greco FA; Dupont J; O'Connor OA
    J Clin Oncol; 2007 Mar; 25(9):1082-8. PubMed ID: 17261851
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia.
    Gimsing P; Hansen M; Knudsen LM; Knoblauch P; Christensen IJ; Ooi CE; Buhl-Jensen P
    Eur J Haematol; 2008 Sep; 81(3):170-6. PubMed ID: 18510700
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and efficacy of patupilone in patients with advanced ovarian, primary fallopian, or primary peritoneal cancer: a phase I, open-label, dose-escalation study.
    Ten Bokkel Huinink WW; Sufliarsky J; Smit WM; Spanik S; Wagnerova M; Hirte HW; Kaye S; Johri AR; Oza AM
    J Clin Oncol; 2009 Jul; 27(19):3097-103. PubMed ID: 19451434
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical and biological effects of recombinant human interleukin-18 administered by intravenous infusion to patients with advanced cancer.
    Robertson MJ; Mier JW; Logan T; Atkins M; Koon H; Koch KM; Kathman S; Pandite LN; Oei C; Kirby LC; Jewell RC; Bell WN; Thurmond LM; Weisenbach J; Roberts S; Dar MM
    Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4265-73. PubMed ID: 16857801
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Monoclonal antibody therapy with mabtera of patients with b-cell low grade non-Hodgkin's lymphoma].
    Karchenko VP; Voznyĭ EK; Belonogov AV; Bozhenko VK; Olfer'ev MA; Galil-Ogly GA
    Vopr Onkol; 2005; 51(1):60-5. PubMed ID: 15909809
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I trial of AEG35156 administered as a 7-day and 3-day continuous intravenous infusion in patients with advanced refractory cancer.
    Dean E; Jodrell D; Connolly K; Danson S; Jolivet J; Durkin J; Morris S; Jowle D; Ward T; Cummings J; Dickinson G; Aarons L; Lacasse E; Robson L; Dive C; Ranson M
    J Clin Oncol; 2009 Apr; 27(10):1660-6. PubMed ID: 19237630
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II study of weekly low-dose paclitaxel for relapsed and refractory non-Hodgkin's lymphoma: a Wisconsin Oncology Network Study.
    Kahl BS; Bailey HH; Smith EP; Turman N; Smith J; Werndli J; Williams EC; Longo WL; Kim KM; McGovern J; Jumonville A
    Cancer Invest; 2005; 23(1):13-8. PubMed ID: 15779863
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.